infectiousdiseaseadvisor.com20h
Twice-Yearly Lenacapavir Gets Priority Review For HIV PrEP
The FDA has accepted under Priority Review the NDA for lenacapavir for the prevention of HIV as pre-exposure prophylaxis.
Gilead Sciences sets aside $200 million to resolve HIV drug probe
Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
bhekisisa.org2h
The Global Fund will roll out the twice-yearly anti-HIV jab — with or without Pepfar
The major backer of the lenacapavir roll-out is assuring nervous researchers that they will keep their part of funding ...
Lawyer Monthly2h
Gilead Sciences Sets Aside $200M for HIV Drug Settlement
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.